AB&B BIO-TECH-B (02627) has recently announced two significant positive developments, drawing market attention. On one hand, the company's self-developed trivalent influenza virus subunit vaccine, the first and only of its kind in China for the entire population with a single dosage, has successfully won a bid in Shanxi Province's procurement project. This marks a rapid transition for this key new product from "approval" to "commercial launch," beginning to generate actual revenue for the company. On the other hand, the company's mRNA vaccine for monkeypox has received Investigational New Drug (IND) clearance from the U.S. FDA, making it the first monkeypox mRNA vaccine from China and the third globally to receive such approval. This indicates international recognition for the research capabilities of its mRNA technology platform. The progress of these two major vaccine products signifies that AB&B BIO-TECH-B has formally entered a new cycle of high-quality development characterized by intensive pipeline advancement and a continuously enriching portfolio of marketed products. As the product matrix becomes increasingly diversified, the company's revenue structure will become more robust, significantly enhancing its ability to withstand market fluctuations of any single product.

In the high-end influenza vaccine sector, the quadrivalent influenza virus subunit vaccine "Huierkangxin®" has driven rapid performance growth for AB&B BIO-TECH-B since its launch in September 2023. Annual revenue for 2025 is projected to reach between 446 million and 493 million yuan, representing a year-on-year increase of 71.8% to 89.9%. Its sales network now covers 30 provinces in China, fully validating its channel capabilities. Early this year, the company's self-developed "Huierkangxin 3," the nation's first and only trivalent influenza virus subunit vaccine for the entire population, was successfully approved for market launch. Together with "Huierkangxin®," it forms a high-end influenza vaccine defense line combining "quadrivalent + trivalent" products. As a third-generation influenza vaccine, Huierkangxin 3 extracts only the virus's surface core antigens, removing internal viral杂proteins, achieving clinical advantages of "higher purity and lower adverse reactions." Phase III clinical data showed its local adverse reaction rate is lower than that of traditional split-virus vaccines. A breakthrough feature is its use of a single 0.5ml dosage for the entire population aged 6 months and above, greatly simplifying the vaccination process. Furthermore, the use of a VVM (Vaccine Vial Monitor) label makes vaccine efficacy "visible to the naked eye," significantly enhancing vaccination safety. Notably, on February 27, the World Health Organization (WHO), in its report on recommended influenza vaccine compositions for the 2026-2027 Northern Hemisphere influenza season, explicitly recommended the prioritized use of trivalent influenza vaccines. As trivalent vaccines are poised to become mainstream, AB&B BIO-TECH-B's trivalent influenza virus subunit vaccine (Huierkangxin 3), priced at 298 yuan per dose, successfully won a bid in Shanxi Province's supplemental procurement project for non-immunization program vaccines. This makes it the first trivalent influenza subunit vaccine for the entire population in China to secure a bid this year. This not only validates the product's market access capability but also indicates its potential for rapid sales volume expansion, injecting new momentum into the company's performance growth.

Beyond the accelerated commercialization of influenza vaccines, AB&B BIO-TECH-B has achieved a milestone in the mRNA vaccine field. The company's mRNA vaccine for monkeypox is the first from China and the third globally to receive IND clearance from the U.S. FDA. Currently, the global monkeypox epidemic situation remains severe. UNICEF has issued an emergency tender for up to 12 million doses of monkeypox vaccine, and the WHO plans to establish a global monkeypox vaccine stockpile by 2026. However, the currently approved monkeypox vaccines abroad are based on attenuated vaccinia virus and replication-deficient vaccinia virus technologies, which have room for improvement in terms of safety, immunogenicity, and production capacity. AB&B BIO-TECH-B's next-generation mRNA monkeypox vaccine is well-positioned to address this significant market gap. The monkeypox mRNA vaccine developed by AB&B BIO-TECH-B utilizes a proprietary innovative tandem design for tetravalent antigens (A27, L1, A33, B5), enabling a single mRNA strand to independently express four antigens. This design has already received a发明专利授权 from the China National Intellectual Property Administration, and the PCT international patent has entered the national phase. In non-clinical studies, the vaccine demonstrated excellent immunogenicity (high levels of binding antibodies, neutralizing antibodies, and cellular immunity) and a favorable safety profile in both SD rat and rhesus monkey models, and provided effective in vivo protection in monkeypox virus challenge tests. Additionally, it boasts advantages for commercial production, including high yield and highly controllable quality, with a single commercial-scale production run capable of yielding millions of vaccine doses. This provides a decisive advantage for rapidly responding to global pandemic needs and market demand in the future.

The progress of the monkeypox mRNA vaccine signifies that AB&B BIO-TECH-B has completed the necessary technical accumulation for developing mRNA vaccines targeting a single pathogen. Looking forward, the company plans to expand into the development of combination vaccines targeting multiple pathogens, such as multi-valent respiratory virus vaccines covering Respiratory Syncytial Virus (RSV), influenza, and human metapneumovirus. Simultaneously, targeting more advanced biopharmaceutical fields, the company is laying out plans for therapeutic cancer vaccines for indications like colorectal cancer and lung cancer, and exploring innovative therapies such as In Vivo CAR-T. Ranging from preventive vaccines to therapeutic cancer vaccines, and from single pathogens to multi-valent combinations, AB&B BIO-TECH-B is building a dual-driven R&D pipeline matrix centered on its mRNA technology platform, encompassing both prevention and treatment. With the ongoing sales expansion of commercial products and the continuous realization of its R&D pipeline, AB&B BIO-TECH-B is further unlocking its future earnings growth potential.